



To NASDAQ OMX Copenhagen A/S
Investor News No. 06-13 / Copenhagen, May 14, 2013

Topotarget A/S
Symbion
Fruebjergvej 3
DK-2100 København
Danmark
Tlf: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr.: 25695771
www.topotarget.com

Shareholder meetings in Copenhagen and Aarhus

Topotarget sends out invitation for shareholder meetings in Copenhagen (Tuesday, June 11, 2013) and Aarhus (Thursday, June 13, 2013).

Topotarget hereby invites the company's shareholders and other interested parties to participate in shareholder meetings on the following dates:

- Tuesday, June 11, 2013 at 4.00 pm CET in Copenhagen – address: Symbion Science Park, Fruebjergvej 3, DK-2100 Copenhagen, room: M2
- Thursday, June 13, 2013 at 4.00 pm CET in Aarhus – address: Radisson Blu Scandinavia Hotel, Margrethepladsen 1, DK-8000 Århus C, room: Plenum

At the meetings, the company's management – led by CEO Anders Vadsholt and Director of Science Jette Tjørnelund – will present Topotarget and the company's strategy. There will moreover be a Q&A session.

Registration must be made by Friday, June 7, 2013 by sending an email with attendee details (name and number of participants) to: investor@topotarget.com.

Topotarget A/S

For further information, please contact:
Anders Vadsholt, CEO: Direct: +45 39178345; Cell: +45 2898905

Background information

About Topotarget

Topotarget (NASDAQ OMX: TOPO) is a Scandinavian-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to the clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.

Topotarget Safe Harbor Statement

This announcement may contain forward-looking statements, including statements about Topotarget A/S' expectations to the progression of Topotarget A/S' clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.